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SuMMAry – ventilator-associated pneumonia (vAP) is very common in many intensive care 
units, but there are still many uncertainties about vAP, especially about the choice of initial empiric 
antibiotics. The incidence of specific pathogens with different susceptibility patterns causing vAP 
varies from hospital to hospital. This is the reason why empiric initial antibiotic treatment for vAP 
should be based not only on general guidelines (that recommend therapy according to the presence 
of risk factors for multidrug-resistant bacteria), but also on up-to-date information on local epidemi-
ology. The aim of this study was to determine the microbial profile of pathogens causing vAP and 
their antibiotic susceptibility patterns. The study was conducted in the 15-bed surgical and neuro-
surgical intensive Care unit, department of Anesthesiology and intensive Care, Sestre milosrdnice 
university hospital Center, Zagreb, Croatia. retrospective data were collected from September 
2009 to March 2013. All patients that developed vAP during the study period were eligible for the 
study. According to study results, the incidence of vAP was 29.4%. The most commonly isolated 
bacterium was Staphylococcus aureus (21.1%), followed by Pseudomonas aeruginosa (19.0%) and Acine-
tobacter species (13.6%). All Staphylococcus aureus isolates were susceptible to vancomycin and line-
zolid. Pseudomonas aeruginosa showed 100% susceptibility to cefepime and very high susceptibility 
to piperacillin-tazobactam (96%), ceftazidime (93%) and ciprofloxacin (89%). Ampicillin-sulbactam 
was highly effective for Acinetobacter species, showing resistance in only 8% of isolates. in conclusion, 
according to study data, appropriate empiric antibiotic therapy for patients with vAP without risk 
factors for multidrug-resistant bacteria is ceftriaxone and for patients with risk factors for multidrug-
resistant bacteria ampicillin-sulbactam plus cefepime plus vancomycin or linezolid.
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Introduction
ventilator-associated pneumonia (vAP) is defined 
as a type of nosocomial pneumonia occurring more 
than 48 hours after initiation of endotracheal intu-
bation and mechanical ventilation1. The incidence of 
vAP ranges from 9% to 27%, so vAP is a very com-
mon problem in intensive care units (iCu), but there 
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are still many uncertainties about vAP, especially 
about the choice of initial empiric antibiotics2,3. An 
inappropriate empiric antibiotic treatment is associ-
ated with increased mortality, prolonged duration 
of mechanical ventilation, prolonged length of iCu 
stay, and increased treatment costs. empiric antibi-
otic therapy should be properly selected according to 
current guidelines, but also adjusted to specific local 
pathogens4. The incidence of specific pathogens with 
different susceptibility patterns causing vAP may not 
only vary from hospital to hospital, but also within 
the same hospital or iCu over time5. This is the rea-
son why empiric initial antibiotic treatment for vAP 
should be based on general guidelines, but also on up-
to-date information on local epidemiology. There is 
a lack of published data from Croatian iCus regard-
ing local microbiological profile of pathogens causing 
vAP, as well as on their antibiotic susceptibility and 
resistance patterns. 
The aim of this study was to determine microbial 
profile of pathogens causing vAP and their antibiotic 
susceptibility patterns. This information will help us 
in selection of appropriate empiric antibiotic therapy.
Patients and Methods
The study was conducted in a 15-bed surgical and 
neurosurgical intensive Care unit of the depart-
ment of Anesthesiology and intensive Care, Sestre 
milosrdnice university hospital Center, Zagreb, 
Croatia. This study was approved by the hospital 
ethics Committee (e.P. number: 35-1/09). retro-
spective data were collected from September 2009 
to March 2013. because of the retrospective and ob-
servational nature of the study, an informed consent 
was unnecessary. 
All patients that developed vAP during the study 
period were eligible for the study. As for clinical diag-
nosis, vAP was established on the Modified Clinical 
Pulmonary infection Score (CPiS) (table 1)6. CPiS 
is based on six clinical assessments, each scored zero 
to two points. A score of more than six was consid-
ered suggestive of vAP. The CPiS score was calcu-
lated only when there was clinical suspicion of vAP 
(presence of new or progressive infiltration on chest 
radiography and presence of at least two of the follow-
ing criteria: fever, leukocytosis and purulent tracheal 
secretion). Also, when there was clinical suspicion of 
vAP, quantitative culture of endotracheal aspirate 
(etA) was performed to identify vAP pathogens. 
Only pathogen isolated at a concentration of more 
than 105 Cfu/ml was considered causative of vAP. 
growth of any organism below the concentration of 
105 Cfu/ml was assumed to be due to colonization. 
etA sample with more than 10 squamous epithelial 
cells per visual field represents an invalid sample7. Pu-
rulent sputum is defined as secretions from the lungs 
that contain more than 25 neutrophils per visual field. 
Only the first vAP episode was evaluated. 
Patient age, gender, smoking habit, Simplified 
Acute Physiology Score ii (SAPS ii), Acute Physi-
ology and Chronic health evaluation ii (APAChe 
ii), comorbidities and main reason for iCu admission 
were recorded. 
early-onset vAP was defined as that occurring 
within the first 4 days of mechanical ventilation (Mv) 
and was more likely to be caused by antibiotic suscep-
tible bacteria. late-onset vAP (after 4 days of Mv) 
Table 1. The Modified Clinical Pulmonary Infection Score (CPIS)
Points 0 1 2
tracheal secretion rare Abundant Abundant + purulent
Chest x-ray infiltrates no infiltrate diffuse infiltrate localized infiltrate
temperature (°C) 36.5-38.4 38.5-38.9 <36 or >39
leukocyte count (/mm3) 4000-11000 <4000 or >11000 <4000 or >11000 + band forms >500
PaO2/fiO2 (mm hg) >240 or ArdS <240 and no evidence of ArdS
Microbiology negative Positive
ArdS = acute respiratory distress syndrome
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was more likely to be caused by multidrug-resistant 
(Mdr) bacteria. Multidrug resistance is defined as 
non-susceptibility to at least one agent from three or 
more antimicrobial categories8. 
Antibiotic susceptibility patterns were determined 
using disc diffusion method and, if required, e-test, 
according to the european Committee on Antimicro-
bial Susceptibility testing (euCASt) standards. The 
antibiotic sensitivity and resistance pattern is shown 
only for the bacteria isolated in more than 9 (10%) 
etA samples. 
Statistical analysis
data entry and analysis were performed using 
MedCalc. The results were expressed as number (%) 
for categorical variables and as median (25th-75th in-
terquartile range) for non-categorical variables.
Results
during the study period, 5071 adult patients were 
admitted to our iCu. four hundred and fifty three 
(8.9%) of these patients were intubated and mechani-
cally ventilated for more than 48 hours. vAP developed 
in 113 out of 453 (24.9%) patients during the iCu stay 
and all these patients were eligible for the study. Clini-
cal characteristics of patients at iCu admission are 
shown in table 2. twenty patients were excluded from 
the analysis (seven patients had invalid sample, six pa-
tients had growth of bacteria below the concentration 
of 105 Cfu/ml, five patients had sterile etA sample, 
and in two patients etA sample was not collected). So, 
the final analysis of bacterial etiology included 93 pa-
tients/etA samples with 147 bacterial species isolated. 
for five bacteria isolated in three etA (Haemophilus 
influenzae, Acinetobacter species, methicillin sensitive 
Staphylococcus aureus, unspecified gram-negative bacte-
ria, unspecified gram-positive bacteria), susceptibility 
profile was not reported, so final analysis of antibiotic 
susceptibility and resistance patterns included 90 pa-
tients with 142 isolated bacteria. 
Among 147 isolated bacteria, 110 (74.8%) were 
gram-negative bacteria (table 3). Pseudomonas aerugi-
nosa was the most common isolated gram-negative 
bacterium, accounting for 28 of 147 (19.0%) isolates. 
The next most commonly isolated bacteria were Acine-
tobacter species, accounting for another 20 (13.6%) 
isolates, followed by Escherichia coli (10.9%), Haemo-
philus influenzae (8.7%), Enterobacter species (8.1%) 
and Klebsiella species (6.2%). The overall proportion of 
gram-positive bacterial species was 37 (25.2%). table 
3 shows that Staphylococcus aureus was the most com-
monly isolated gram-positive bacterium. Among all 
Staphylococcus aureus isolates, 15 (48.4%) isolates were 
methicillin resistant S. aureus (MrSA). Staphylococ-
cus aureus was the most common cause of vAP, ac-
counting for 31 (21.1%) of total isolated bacteria. in 
20 etA samples, mixed bacterial and fungal species 
were isolated. twenty-one fungal isolates included 
yeasts and moulds. There were 18 Candida species and 
3 Aspergillus species isolated.
Out of 93 patients that developed vAP, 41 (44.1%) 
died. Sixty-six bacteria were isolated in etA sam-
Table 2. Characteristics of VAP patients at ICU admis-
sion 
number of patients 113
Men 72 (63.7)
Age (years)  68 (56-77)
Smokers 23 (20.4)
SAPS ii 37 (27-48)
APAChe ii 15 (10-18)
Comorbidities:
diabetes mellitus 19 (16.8)
Malignant disease 15 (13.3)
COPd 16 14.2)
Chronic cardiac disease 28 (24.8)
Kidney failure 8 (7.1)
hypertension 52 (46)
Alcoholism 15 (13.3)
Main reason for iCu admission:
Medical* 3 (2.7)
trauma without surgery 5 (4.4)
Surgery 105 (92.9)
head 45 (39.8)
neck and thorax 3 (2.7)
Abdominal 45 (39.8)
trauma 12 (10.6)
results are presented as median (25th-75th interquartile range), or as 
number (%); vAP = ventilator-associated pneumonia; iCu = intensive 
care unit; SAPS ii = Simplified Acute Physiology Score ii; APAChe 
ii = Acute Physiology and Chronic health evaluation ii; COPd = 
chronic obstructive pulmonary disease; *acute respiratory failure, sepsis, 
state post-resuscitation
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ples of these patients. gram-negative bacteria were 
the cause of death in 72.7% of all bacteria isolated in 
deceased patients. The highest mortality rate was re-
corded in patients infected with Klebsiella species, i.e. 
six of nine (66.7%), followed by MrSA (60.0%) and 
Pseudomonas aeruginosa (53.6%) (table 4). 
Out of 147 isolated bacteria, 93 (63.3%) were cat-
egorized under early-onset vAP and 54 (36.7%) un-
der late-onset vAP. Staphylococcus aureus, Pseudomo-
nas aeruginosa, and Acinetobacter species were the 
most common isolates in the early-onset and late-
onset vAP. Staphylococcus aureus and Pseudomonas 
aeruginosa were more frequently isolated in etA 
from patients with late-onset vAP as compared to 
those with early-onset vAP (26.0% vs. 18.2% and 
26.0% vs. 15.0%). Acinetobacter species was more fre-
quently isolated from patients with early-onset vAP 
compared to patients with late-onset vAP (15.1% vs. 
11.1%) (table 3). 
Monomicrobial infection occurred in 54 of 93 
(58.1%) patients, and polymicrobial infection in 39 
(41.9%) patients, 27 of which were infected with two 
pathogens, ten with three pathogens, and two with 
four pathogens. 
figure 1 shows antimicrobial susceptibility and re-
sistance patterns of the most commonly isolated bac-
teria. Among Staphylococcus aureus isolates, 15 (50%) 
were susceptible and 15 (50%) resistant to cloxacillin. 
All S. aureus isolates were susceptible to vancomycin 
and linezolid. All Haemophilus influenzae isolates were 
susceptible to 2nd and 3rd generation cephalosporins. 
Antibiotic susceptibility and resistance patterns of 
Enterobacter species, Klebsiella species and Escherichia 
coli are shown together under Enterobacteriaceae. En-
Table 3. Bacterial species isolated from ETA samples in VAP patients 
early-onset vAP
(≤4 days of Mv)
late-onset vAP
(>4 days of Mv)
total number of isolated bacteria 147 93 (63.3) 54 (36.7)
gram-negative bacteria: 110 (74.8) 73 (66.3) 37 (33.7)
Moraxella catarrhalis 2 (1.4) 2 (100) 0
Haemophilus influenzae 13 (8.7) 9 (69.2) 4 (30.8)
Pseudomonas aeruginosa 28 (19) 14 (50) 14 (50)
Acinetobacter species 20 (13.6) 14 (70) 6 (30)








e Escherichia coli 16 (10.9) 13 (81.2) 3 (18.8)
Klebsiella species 9 (6.2) 9 (100) 0
Enterobacter species 12 (8.1) 8 (66.7) 4 (33.3)
Proteus mirabilis 2 (1.4) 0 2 (100)
Serratia species 3 (2.1) 2 (66.7) 1 (33.3)
Citrobacter species 2 (1.4) 1 (50) 1 (50)
unspecified gram-negative bacteria 1 (0.7) 0 1 (100)
gram-positive bacteria: 37 (25.2) 20 (54.1) 17 (45.9)
Staphylococcus aureus 31 (21.1) 17 (54.8) 14 (45.2)
Streptococcus pneumoniae 4 (2.7) 2 (50) 2 (50)
β-hemolytic Streptococcus group b 1 (6.8) 1 (100) 0
unspecified gram-positive bacteria 1 (0.7) 0 1 (100)
fungi 21 16 5
Aspergillus 3 2 1
Candida 18 14 4
results are presented as number of bacterial species isolates (% of the number of total isolated bacteria); vAP = ventilator-associated pneumonia; 
Mv = mechanical ventilation; etA = endotracheal aspirate
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terobacter species isolates were in more than 65% of 
cases susceptible to sulfamethoxazole-trimethoprim 
and ciprofloxacin and in more than 80% of all isolates 
were susceptible to cefepime. Among Klebsiella species 
isolates, 3 (33.3%) were extended spectrum beta-lacta-
mase (eSbl) producers and were resistant to 2nd and 
3rd generation cephalosporins. All Escherichia coli iso-
lates were susceptible to 2nd and 3rd generation cepha-
losporins. Pseudomonas aeruginosa showed 100% sus-
ceptibility to cefepime and very high susceptibility to 
piperacillin-tazobactam (96%), ceftazidime (93%) and 
ciprofloxacin (89%). Among Acinetobacter species, 63% 
of isolates had decreased susceptibility to meropenem, 
and 58% decreased susceptibility to imipenem. Ampi-
cillin-sulbactam was highly effective for Acinetobacter 
species, showing resistance in only 8% of isolates. 
Among 142 isolated bacteria with susceptibility 
and resistance pattern, 102 (71.8%) were resistant bac-
teria, 42 (41.7%) of which were Mdr bacteria (table 
5). The most common resistant bacteria were Acine-
tobacter species (100%), Klebsiella species (100%) and 
MrSA (100%). Acinetobacter species and MrSA were 
Mdr bacteria in all etA samples. Klebsiella species 
were Mdr in 44.4%, followed by Enterobacter species 
that were Mdr in 16.7% of cases and Escherichia coli 
that were Mdr in 6.3% of all isolates. Pseudomonas 
aeruginosa was Mdr in only 3.6% of cases.
Discussion
Through this research, we determined the anti-
biotic susceptibility patterns of gram-positive and 
gram-negative bacteria causing vAP, as well as the 
Table 4. Mortality associated with most commonly isolated 
bacteria
bacteria
Mortality due to specific 
bacteria
n (%)
Pseudomonas aeruginosa 15 (53.6)
Acinetobacter species 10 (52.6)
Escherichia coli 6 (37.5)
Haemophilus influenzae 3 (25)
Enterobacter species 4 (33.3)
Klebsiella species 6 (66.7)
MSSA 6 (37.5)
MrSA 9 (60)
results are presented as number of bacterial species isolates in patients 
died (% of total number of each isolated bacterium); MSSA = methicillin 
sensitive Staphylococcus aureus; MrSA = methicillin resistant Staphylo-
coccus aureus
Table 5. Antibiotic resistance of the most commonly isolated 
bacteria
bacteria
total number of each iso-
lated bacterium/number of 










Mdr = multidrug resistant; MSSA = methicillin sensitive Staphylococ-
cus aureus; MrSA = methicillin resistant Staphylococcus aureus
Table 6. Initial empiric therapy for VAP according to the 
American Thoracic Society12
vAP with no risk 
factors for Mdr 
pathogens



























linezolid or vancomycin (if risk 
factors for MrSA are present)
vAP = ventilator-associated pneumonia; Mdr = multidrug resistant; 
MrSA = methicillin resistant Staphylococcus aureus
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frequent causative microorganisms of early- and 
late-onset vAP in our iCu. The microbial profile of 
pathogens causing vAP may differ between hospitals 
and iCu settings, even within the same institution 
between different iCus. Therefore, surveillance of 
bacterial susceptibility should be conducted and lo-
cal epidemiological data should be provided for every 
iCu4. This information can help in guiding the initial 
empiric antibiotic therapy, which would be helpful in 
decreasing mortality and preventing development of 
Mdr bacteria9-11. Antibiotic choices based on pub-
lished guidelines may be ineffective if local microbial 
flora shows different susceptibility patterns. 
According to the American Thoracic Society, em-
piric antibiotic selection for vAP should be based on 
the time of vAP onset and on the presence of risk fac-
tors for Mdr bacteria12. Whereas early-onset vAP is 
more likely to be caused by antibiotic-sensitive bac-
teria, late-onset vAP is more likely to be caused by 
Mdr pathogens. The most common Mdr bacteria 
are Pseudomonas aeruginosa, Acinetobacter baumannii, 
resistant Enterobacteriaceae species and MrSA. risk 
factors for acquiring Mdr bacteria are antibiotics 
and hospitalization in the preceding 90 days, current 
hospitalization longer than 5 days, duration of me-
chanical ventilation longer than 7 days, immunosup-
pressive therapy or disease, high frequency of anti-
biotic resistance in the iCu, home infusion therapy 
or wound care, chronic dialysis within 30 days, and 
family member with Mdr pathogen or residence in a 
nursing home or extended-care facility. Patients with 
early-onset vAP who have risk factors for Mdr bac-
teria are at a greater risk of colonization and infection 
with Mdr pathogens and should be treated similar to 
patients with late-onset vAP. The American Thoracic 
Society guidelines shown in table 6 suggest that pa-
tients who do not have risk factors for Mdr bacteria 
should be treated with ceftriaxone or fluoroquinolone 
or ampicillin + sulbactam or ertapenem. When pa-
tients are at risk of the occurrence of Mdr bacteria, 
initial empiric therapy should be broad-spectrum and 
effective against Mdr pathogens. A recommended 
empiric regimen for patients with risk factors for 
Mdr bacteria is an antipseudomonal cephalosporin 
(cefepime, ceftazidime) or an antipseudomonal car-
bapenem (imipenem, meropenem) or beta-lactam/
beta-lactamase inhibitor (piperacillin-tazobactam) 
 Fig. 1. Antibiotic susceptibility and resistance of the most 
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plus an antipseudomonal fluoroquinolone (ciprofloxa-
cin, levofloxacin) or an aminoglycoside (amikacin, 
gentamicin, tobramycin) plus either linezolid or van-
comycin. 
Although empiric antibiotic therapy selection 
can be guided by gram stain and preliminary bacte-
rial culture results of etA samples, most important 
guidance in selection of appropriate antibiotic therapy 
is the presence or absence of risk factors for Mdr 
pathogens. 
it has been assumed that early-onset vAP is caused 
by antibiotic susceptible, community acquired, micro-
bial pathogens colonizing oro- and nasopharyngeal 
secretions, such as Streptococcus pneumoniae, Haemo-
philus influenzae, Moraxella catarrhalis and Staphylococ-
cus aureus. late-onset vAP is often associated with 
resistant causative microorganisms since patient colo-
nization with Mdrs is expected during prolonged 
iCu stay. however, paradigms have changed. 
Most cases of vAP in our setting are those of 
early-onset vAP (63.3%). According to many studies, 
early-onset vAP is more likely to be caused by antibi-
otic-sensitive bacteria, while late-onset vAP is more 
likely to be caused by Mdr bacteria. Microbial flora 
present in oral cavity of intubated patients changes 
during hospitalization because protective mechanisms 
decline in critically ill patients due to the reduction 
of salivary secretion, lower levels of salivary local im-
munity factors, and absence of self-cleaning by chew-
ing. in such conditions, dental plaque and oral mucosa 
in hospitalized patients become colonized by more 
pathogenic and often resistant microbial species13.
Our data revealed that Mdr pathogens, such as 
Acinetobacter species and MrSA, are present at almost 
the same frequency in early- and late-onset vAP. for 
example, Acinetobacter species were numerically high-
er among early-onset vAP subjects as compared to 
late-onset vAP subjects, although many studies have 
shown that Acinetobacter species are a major causative 
agent of late-onset vAP14. Similar results have been 
reported by restrepo et al. and ibrahim et al., who 
demonstrated that there were no differences in the 
rate of potential Mdr bacteria between early-onset 
and late-onset vAP15,16. These results are expected 
since many patients admitted to iCu have numerous 
risk factors predisposing previous colonization with 
Mdr bacteria17,18. Our finding also indicated that the 
causative pathogens varied in different setups and de-
pended not only on the time of vAP onset, but also on 
the characteristics and diagnoses of patients admitted 
to iCu, as well as on the presence of risk factors for 
Mdr bacteria. 
earlier reports have shown that different gram-
negative bacteria are the most common causative agent 
of vAP. in our study, 74.8% of vAP cases were caused 
by gram-negative bacteria, which is consistent with 
similar studies where approximately 60% of bacteria 
were found to be gram-negative bacteria19. Among 
gram-positive bacteria, the most common bacterial 
species isolated in the study period was Staphylococcus 
aureus, with a high resistance rate. MrSA was isolat-
ed in 15 (48.4%) cases. All MrSA isolates were sus-
ceptible to vancomycin and linezolid, making these 
antimicrobials drugs of choice for empiric antibiotic 
therapy for vAP caused by gram-positive bacteria. As 
demonstrated by the ZePhyr study results, linezolid 
has superiority over vancomycin in clinical outcome 
of MrSA pneumonia, due to its pharmacokinetic 
and pharmacodynamic properties. hence, it should 
be considered as the antibiotic of choice. Also, in our 
study, Staphylococcus aureus was the most frequently 
isolated species, accounting for 54.1% of isolates in 
early-onset vAP and 45.9% of isolates in late-onset 
vAP. According to Park et al., one of the risk factors 
for vAP caused by Staphylococcus aureus is neurosurgi-
cal procedure as the reason for iCu admission, and 
our patient cohort included almost 40% of neurosur-
gical patients20.
According to our data, appropriate empiric antibi-
otic therapy for patients with vAP without risk factors 
for Mdr bacteria is ceftriaxone since non-Mdr bac-
teria isolated in our patients were susceptible to cef-
triaxone. Appropriate empiric antibiotic therapy for 
patients with risk factors for Mdr bacteria, according 
to present data, is ampicillin-sulbactam plus cefepime 
plus vancomycin or linezolid. Ampicillin-sulbactam 
should be part of empiric regimen for Acinetobacter 
species. Cefepime should be added due to the high 
frequency of vAP caused by Pseudomonas aeruginosa. 
Enterobacteriaceae species also showed high suscep-
tibility to cefepime. vancomycin or linezolid should 
be part of regimen because Staphylococcus aureus is the 
most frequent isolate with high methicillin resistance 
rates. 
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The most common vAP pathogen associated with 
mortality was Klebsiella species, accounting for 66.7% 
of overall mortality. Although the overall number of 
patients with vAP caused by Klebsiella species was 
small, the reasons for such outcome may be numerous 
virulence factors expressed in this bacterial species. 
yeasts and moulds isolated in our patients that 
developed vAP (n=21) were considered as coloniza-
tion of tracheal secretions and were not counted in the 
vAP causative microorganism analysis.
The significance of fungal isolates in tracheobron-
chial secretions in patients with vAP is unclear and is 
a subject of numerous studies. Although fungal spe-
cies are not common causative agents of vAP in non-
neutropenic critically ill patients, and usually are con-
sidered as colonization, there are reports of Candida 
species impact on innate immune response, immuno-
suppression, and subsequent worse clinical outcomes 
in patients with vAP caused by Mdr bacteria due to 
the Candida immunomodulatory mechanisms21,22. 
Our study had a few limitations. One was the 
length of study period during which susceptibility 
patterns of Acinetobacter species had shifted towards 
resistance patterns. According to the national anti-
biotic resistance data provided by the Committee for 
Antibiotic resistance Surveillance in Croatia, ampi-
cillin-sulbactam resistance in Acinetobacter species was 
13% in 2009, while resistance rates increased to 19% 
in 2012. This trend shows that local epidemiology data 
should be updated. Another limitation was the lack of 
correlation between specific risk factors and early- or 
late-onset vAP and Mdr causative microorganisms.
This study has set up new research goals. further 
surveillance of microbial profile and susceptibility 
patterns in our iCu should be conducted regularly in 
order to detect potential alterations, especially since 
new resistant bacterial strains are emerging through-
out south-east europe. Other research goals should 
be determination of characteristics and diagnoses of 
patients developing vAP, presence of risk factors for 
Mdr bacteria infection, and correlation of specific 
Mdr bacteria with mortality.
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Sažetak
MiKrObiOlOŠKi PrOfil i AntibiOtSKA OSJetlJivOSt uZrOčniKA ventilACiJSKe 
PneuMOniJe u JediniCi intenZivnOg liJečenJA KliničKOg bOlničKOg CentrA SeStre 
MilOSrdniCe, ZAgreb, hrvAtSKA
T. Magdić Turković, A. Gverić Grginić, B. Đuras Cuculić, B. Gašpar, M. Širanović i M. Perić
ventilacijska pneumonija (vAP) je vrlo česta u jedinicama intenzivnog liječenja, ali još uvijek postoje mnoge nedou-
mice vezane uz vAP, osobito što se tiče početnog empirijskog odabira antibiotika za liječenja vAP-a. učestalost pojedinih 
patogena s različitom osjetljivošću na antibiotike razlikuje se od bolnice do bolnice. to je razlog zbog kojeg bi se empirijska 
antibiotska terapija trebala temeljiti ne samo na općim smjernicama (koje preporučuju terapiju na temelju prisutnosti ri-
zičnih čimbenika za bakterije rezistentne na više lijekova), nego i na podacima o lokalnoj epidemiologiji. Cilj ovoga istra-
živanja je bio utvrditi mikrobiološki profil patogena koji uzrokuju vAP i njihovu osjetljivost na antibiotike. istraživanje je 
provedeno u 15-krevetnoj Jedinici intenzivnog liječenja Odjela za anesteziologiju, reanimatologiju i intenzivno liječenje 
Kliničkog bolničkog centra “Sestre milosrdnice”, Zagreb, hrvatska. Podaci su skupljani retrospektivno od rujna 2009. 
do ožujka 2013. godine. Svi bolesnici kod kojih se razvila vAP tijekom navedenog razdoblja su uključeni u istraživanje. 
Prema našim rezultatima, incidencija vAP-a bila je 29,4%. najčešće izolirana bakterija je bila Staphylococcus aureus (21,1%), 
iza koje slijede Pseudomonas aeruginosa (19,0%) i Acinetobacter sp. (13,6%). Svi izolati bakterije Staphylococcus aureus su bili 
osjetljivi na vankomicin i linezolid. Pseudomonas aeruginosa je u 100% izolata bio osjetljiv na cefepim te visoko osjetljiv na 
piperacilin-tazobaktam (96%), ceftazidim (93%) i ciprofloksacin (89%). Ampicilin-sulbaktam se pokazao vrlo učinkovi-
tim za Acinetobacter sp. s rezistencijom u samo 8% izolata. u zaključku, prema našim rezultatima, empirijska antibiotska 
terapija za bolesnike s vAP-om bez rizika za bakterije rezistentne na više lijekova je ceftriakson, a za bolesnike s rizičnim 
čimbenicima za bakterije rezistentne na više lijekova je ampicilin-sulbaktam plus cefepim plus vankomicin ili linezolid. 
Ključne riječi: Pneumonija, izazvana ventilacijom – etiologija; Lijekovi, rezistencija, bakterijska; Jedinice za intenzivnu 
skrb; Hrvatska 
